Takeda predicts that climate change will help its Zika and dengue fever vaccines find a larger market. Roche says it could ultimately make it attractive for the company to develop treatments for diseases like malaria. And AbbVie says extreme weather events might boost its immunology products.

But the potential risks of climate change — and the attendant increase in natural disasters — stand to outstrip any of those incremental gains, as the companies described in recent risk assessment reports to the British nonprofit CDP.

Read the rest…

Source link